Polaryx Therapeutics Inc 2025年度报告

(Mark one)☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December31, 2025 OR For the transition period fromtoCommission File Number: 001-43080 Polaryx Therapeutics, Inc.(Exact name of registrant as specified in its charter) South Tower, 140 E Ridgewood Avenue, Suite 415Paramus, NJ 07652(201) 940-7236(Address including zip code, and telephone number including area code, of registrant’s principal executive offices) Former name, former address and former fiscal year, if changed since last report: N/A Securities registered pursuant to Section 12(b) of the Exchange Act: Title of each classTrading Symbol(s)Name of each exchange on whichregisteredCommon Stock, par value $0.0001 per Securities registered pursuant to Section 12(g) of the Exchange Act: None. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes☐No☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes☐No☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒Emerging growth company☒ Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectivenessof its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registeredpublic accounting firm that prepared or issued its audit report.☐ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of theregistrant included in the filing reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-basedcompensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ The registrant was not a public company as of the last business day of its most recently completed second fiscal quarter and thereforecannot calculate the aggregate market value of the voting and non-voting common equity held by non-affiliates as of such date. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of February 1, 2026, the registrant had 47,343,297 shares of common stock, $0.0001 par value per share, outstanding. DOCUMENTS INCORPORATED BY REFERENCE None. TABLE OF CONTENTS PART I11. Business11A. Risk Factors671B. Unresolved Staff Comments1091C. Cybersecurity1092. Properties1093. Legal Proceedings1094. Mine Safety Disclosures109PART II1105. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities1106. Reserved1107. Management’s Discussion and Analysis of Financial Condition and Results of Operations1117A. Quantitative and Qualitative Disclosures about Market Risk1188. Financial Statements and Supplementary DataF-19. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure1199A. Controls and Procedures1199B. Other Information1199C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections119PART III12010. Directors, Executive Officers and Corporate Governance12011. Executive Compensation12312. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters12813. Certain Relationships and Related Transactions, and Director Independence13014. Principal Accountant Fees and Services133PART IV13415. Exhibits13416. Form 10-K Summary134Signatures135 SPECIA